.jpg)
.jpg)
UCLA Institute of Urologic Oncology
Dr. Pantuck is Professor of Urology at the David Geffen School of Medicine at UCLA, Vice Chair of Academic Affairs for the Department of Urology, Executive Chair of the UCLA IRB, a member of the Executive Committee of the Institute of Urologic Oncology, former Director of the UCLA SUO Urologic Oncology Fellowship program, and former Director of the GU Oncology Program of the UCLA Jonsson Comprehensive Cancer Center
Dr. Pantuck completed his medical degree and residency in Urology at the Robert Wood Johnson Medical School. He then completed a 3-year Society of Urologic Oncology fellowship in urologic oncology at UCLA, doing basic research in gene and immune therapy of GU cancers with National Institutes of Health grant support under the mentorship of Dr. Arie Belldegrun. Dr. Pantuck completed a Master of Science Degree in Clinical Research and has received NIH funding for translational research in the development of molecular and genomic diagnostics for cancer. With twenty years of experience in the design and implementation of gene and immune-based clinical trials, Dr. Pantuck is certified by the American Board of Urology and a Fellow of the American College of Surgeons.
Dr Pantuck is also on the scientific and advisory boards of several biotechnology and pharmaceutical companies, and was a co-founder of and scientific consultant to Kite Pharma (acquired by Gilead) which was awarded FDA approval for Yescarta, a novel engineered T-cell immunotherapy for Non-Hodgkin’s Lymphoma, in 2018. Dr. Pantuck is currently a founder and Chair of the Board of Directors of Athos Therapeutics. In addition to authoring several pending US patent applications, Dr. Pantuck has written over 300 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.
Disclosure information not submitted.
Sunday, May 15, 2022
2:45 PM – 4:00 PM